Reports for Release Therapeutics SA
Credit rating information
Evaluation of credit rating with traffic light as risk indicator and other helpful data about the company.Find out more
Economic information
Comprehensive information about the economic situation of a company.Find out more
Payment collection information
Overview of current and past debt enforcement proceedings.Find out more
Shareholder Information
Find out which national and international companies the stock corporation you are interested in also holds shares in.Find out more
Company dossier as PDF
Contact information, changes in the company, turnover and employee figures, management, ownership, shareholding structure and other company data.Retrieve company dossier
About Release Therapeutics SA
- Release Therapeutics SA has its legal headquarters in Genève, is active and operates in the sector «Research and development».
- The management consists of 4 persons. The company was founded on 20.12.2005.
- All past changes can be viewed and saved as a PDF under the section «Notifications». The last change in the commercial register was made on 19.09.2025.
- The company is registered in the commercial register GE under the UID CHE-112.690.021.
- In the IPI there are 6 trademarks or applications registered by the company Release Therapeutics SA.
- Companies with the same address as Release Therapeutics SA: ARB Biotech Sàrl, Association Genilem, Association Health Innovation and Investment Exchange.
Management (4)
newest board members
newest authorized signatories
Julien Nicolas Grogg,
Nicolas Mach,
Clarence Georges Peter,
Feisal Abukscem
Commercial register information
Entry in the commercial register
20.12.2005
Legal form
Company limited by shares (AG)
Legal headquarters of the company
Genève
Commercial Registry Office
GE
Commercial register number
CH-660.2.780.005-1
UID/VAT
CHE-112.690.021
Sector
Research and development
Purpose (Original language)
La recherche, le développement et la commercialisation de thérapies innovantes notamment dans les domaines du traitement de maladies génétiques et de la vaccination. Elle peut également effectuer toutes opérationscommerciales, financières ou industrielles se rapportant directement ou indirectement à son but.
Auditor
Current auditor (1)
| Name | City | Since | Until | |
|---|---|---|---|---|
| Ypsom Partners Sàrl | Genève | 09.10.2024 | ||
Former auditor (2)
| Name | City | Since | Until | |
|---|---|---|---|---|
| CCCG SA | Genève | 07.03.2014 | 08.10.2024 | |
| Finova Genève SA | Genève | 27.12.2005 | 06.03.2014 | |
Other company names
Branches (0)
Ownership structure
Holdings
Trademarks
| Trademark | Registration date | Status | Number |
|---|---|---|---|
| to the trademark | 17.01.2024 | active | 14196/2023 |
| 17.01.2024 | active | 14196/2023 |
Newest SOGC notifications: Release Therapeutics SA
The latest updates from the Swiss Official Gazette of Commerce (SOGC) are available in the original language of the source commercial register office only. View all notifications
Publication number: HR02-1006438236, Commercial Registry Office Geneva, (660)
Release Therapeutics SA, à Genève, CHE-112.690.021 (FOSC du 28.03.2025, p. 0/1006295087). Augmentation ordinaire du capital-actions porté de CHF 1'036'041, 4 à CHF 1'115'069, 2, soit d'un montant de CHF 79'027.80, par l'émission de 790'278 actions de CHF 0.10, nominatives.
Capital-actions:
CHF 1'115'069, 2, entièrement libéré, divisé en 11'150'692 actions de CHF 0.10, nominatives.
Communication aux actionnaires:
par écrit (courrier simple ou fax) ou par courriel. Nouveaux statuts du 09.09.2025, modifiés le 09.09.2025.
Publication number: HR02-1006295087, Commercial Registry Office Geneva, (660)
Release Therapeutics SA, à Genève, CHE-112.690.021 (FOSC du 09.10.2024, p. 0/1006150135). Pavletic Aranicki Ksenija n'est plus administratrice;
ses pouvoirs sont radiés. Les pouvoirs de Mehrling Thomas Jörg sont radiés. Signature collective à deux a été conférée à Grogg Julien Nicolas, de Thunstetten, à Lutry, directeur.
Publication number: HR02-1006150135, Commercial Registry Office Geneva, (660)
Release Therapeutics SA, à Genève, CHE-112.690.021 (FOSC du 18.06.2024, p. 0/1006060514).
Nouveau but:
la recherche, le développement et la commercialisation de thérapies innovantes notamment dans les domaines du traitement de maladies génétiques et de la vaccination. Elle peut également effectuer toutes opérationscommerciales, financières ou industrielles se rapportant directement ou indirectement à son but. Statuts modifiés le 16.09.2024. CCCG SA (CHE-103.217.714) n'est plus organe de révision.
Nouvel organe de révision:
Ypsom Partners Sàrl (CHE-418.713.722), à Genève.
Hit list
Here you will find a link from the management to a hit list of persons with the same name who are registered in the commercial register.